China Meheco reports Q3 2025 earnings dip, updates disclosure policies

China Meheco reported cumulative operating revenue of 25.894 bn yuan for the first three quarters of 2025, a decrease of 3.42% year-over-year. Net profit attributable to shareholders was 454.76m yuan, down 4.64% compared to the previous year. The company noted that ongoing challenges from volume-based procurement and medical insurance cost controls, coupled with intensified industry competition, narrowed profit margins despite proactive transformation efforts.

The company's board of directors approved the third-quarter 2025 report and revised several key management policies. These include updates to the "Information Disclosure Affairs Management System," "Interbank Bond Market Debt Financing Tools Information Disclosure Management System," "Company Bond Information Disclosure Management System," and "Information Disclosure Suspension and Exemption Management System." These revisions aim to enhance regulatory compliance and improve transparency in information disclosure.

Additionally, the company announced the successful resolution of a 2021 contract dispute, resulting in the transfer of assets totaling 9.391m yuan to its subsidiary. It also completed the transfer of a 5% limited partnership share in a life and health industry fund, with China Meheco waiving its priority right to acquire the shares.